Amgen, Neumora Collaborate On Precision Therapies for Brain Diseases

Amgen Inc AMGN and Neumora Therapeutics Inc have announced a strategic collaboration to advance neuroscience discovery, development, and commercialization.
The companies will collaborate on programs by applying Neumora's proprietary precision neuroscience platform to insights generated by Amgen's deCODE genetics and human data research capabilities.
Deal terms for the collaboration were not disclosed.
In addition, Neumora has received a $100 million equity investment from Amgen and acquired exclusive global rights to Amgen programs targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases.
Related: Amgen's Lumakras Combo Therapy Shows Improved Response Rate In Colorectal Cancer.
Price Action: AMGN stock closed 0.89% lower at $209.98 on Wednesday.